Rise of the mutants: Report from the 19th conference of the European Haematology Association, Milan, 12-15 June 2014

Research output: Contribution to journalArticlepeer-review

Abstract

At the 19th conference of the European Haematology Association in Milan, we saw the true and dramatic changes brought about by the integration of extensive genomic information in clinical practice, and the dilemmas that accompany such a rapid increase in knowledge. Each disease is sliced more and more into smaller pieces, each with its own better-determined outcome and treatment. We also observed the rise of mutant-specific epigenetic agents, which benefit from knowing the underlying genetic abnormality to specifically assign an epigenetic drug where it is needed. In contrast to the 'one mutation, one drug' approach, others are pursuing the search for drugs targeting pathways fundamental for the survival of all or most cancer cells, sometimes looking at more 'exotic' pathways like neddylation or nuclear export. Copyright:

Original languageEnglish
Article number453
Journalecancermedicalscience
Volume8
Issue number1
DOIs
Publication statusPublished - Aug 18 2014

Keywords

  • Acute myeloid leukaemia
  • Chronic lymphoid leukaemia
  • Epigenetic
  • Sequencing
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Rise of the mutants: Report from the 19th conference of the European Haematology Association, Milan, 12-15 June 2014'. Together they form a unique fingerprint.

Cite this